• Jiedu Xiaozheng Yin Shifts Macrophage Polarization in CAC vi

  2026-07-20

  Liu et al. reveal that Jiedu Xiaozheng Yin (JXY) suppresses colitis-associated colorectal cancer (CAC) progression by promoting macrophage polarization toward the M1 phenotype via the TLR4 pathway. These findings provide mechanistic insights into immune reprogramming in CAC and highlight potential targets for chemoprevention.

• Biotin-Free Proximity Labeling in T Cells via Click-Compatib

  2026-07-20

  This study introduces a copper-dependent BmTyr tyrosinase platform for bioorthogonal, biotin-free proximity labeling in primary T cells. By enabling clickable conjugation to azide tags and facilitating direct, antibody-independent proteomic mapping, the approach overcomes limitations of background biotinylation, expanding the precision and applicability of subcellular proteome profiling.

• Levofloxacin (SKU B1959): Data-Driven Solutions for Cell Ass

  2026-07-19

  This article delivers an evidence-based, scenario-driven guide for leveraging Levofloxacin (SKU B1959) in cell viability, proliferation, cytotoxicity, and antibacterial workflows. By addressing real laboratory challenges and providing quantitative context, the piece helps researchers select and implement Levofloxacin with confidence in reproducibility and assay specificity.

• Intravesical p21 mRNA-LNP: Advancing Bladder Cancer Therapy

  2026-07-18

  This study establishes localized p21 mRNA-loaded lipid nanoparticles (LNPs) as a tumor suppressor replacement therapy for bladder cancer. By restoring p21 expression through intravesical delivery, the approach achieves robust tumor inhibition and minimal systemic exposure, offering a promising alternative to conventional treatments.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-17

  Schwartz's dissertation introduces a critical distinction between relative and fractional viability in the in vitro evaluation of anticancer agents, illuminating how conventional metrics can obscure nuanced drug effects. These findings offer a methodological advance that enables more precise interpretation of antiproliferative and cytotoxic responses, informing both drug discovery and translational research.

• Bile Acid Metabolism Subtypes Identify Prognostic CRC Marker

  2026-07-17

  Feng et al. (2026) introduce an integrative molecular subtyping of colorectal cancer based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key markers associated with immune dysfunction and prognosis. This approach provides mechanistic insight into tumor microenvironment heterogeneity and establishes a framework for future translational biomarker studies.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-07-16

  5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a selective α2-adrenergic receptor agonist enabling reproducible research in immune rejection modulation and post-surgery osteosarcoma recurrence. Its robust DMSO solubility, high purity, and well-characterized action make it a reliable tool for dissecting α2-AR signaling pathways. This article provides protocol parameters, evidence benchmarks, and clarifies common misconceptions.

• YAP-TEAD Orchestrates Super-Enhancer Networks in Surface Ect

  2026-07-16

  This study uncovers how the YAP-TEAD transcriptional complex regulates super-enhancer networks to guide early surface ectoderm commitment during stem cell differentiation. By integrating genome-wide profiling and functional perturbation, the research provides new insight into the epigenetic control of lineage decisions, with implications for regenerative medicine and epithelial tissue engineering.

• Baicalein: Applied Workflows for Cancer and Inflammation Res

  2026-07-15

  Baicalein (5,6,7-trihydroxy-2-phenylchromen-4-one) stands out as a potent tool for dissecting cancer cell proliferation and inflammation pathways. This guide dives into optimized protocols, troubleshooting, and workflow enhancements that leverage Baicalein’s unique biochemical properties for robust experimental outcomes.

• WZ4003: Precision NUAK1/2 Inhibition for Cell and Brain Assa

  2026-07-15

  WZ4003, a potent NUAK1/2 inhibitor from APExBIO, enables high-specificity dissection of cell migration, proliferation, and tau phosphorylation pathways. Recent breakthroughs demonstrate its dual value in both cancer and Alzheimer’s disease research, empowering robust experimental workflows and new therapeutic insights.

• BI 2536: Precision PLK1 Inhibitor for Cell Cycle and Cancer

  2026-07-14

  BI 2536 is a potent, selective PLK1 inhibitor that induces G2/M arrest and apoptosis in cancer cells. This article details its mechanism, benchmarks, and best practices for research use, with evidence from both primary literature and product documentation.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix T

  2026-07-14

  The referenced study demonstrates that a transient 'testosterone bounce'—a temporary rise in serum testosterone above 20 ng/dL after nadir—serves as a robust predictor of overall and cancer-specific survival in prostate cancer patients treated with degarelix. This finding introduces a practical, biomarker-driven approach to risk stratification beyond traditional PSA monitoring, informing both clinical practice and translational research.

• Cdk5 Downregulation Mitigates Neuronal Ferroptosis via AMPK

  2026-07-13

  This study demonstrates that targeting Cdk5 reduces ferroptosis in hippocampal neurons after ischemic stroke by modulating AMPK signaling and microglial activation. These findings clarify mechanisms linking neuroinflammation, iron metabolism, and cell death, providing new targets for neuroprotection in stroke.

• gamma-Glu-Cys (γ-Glu-Cys): Practical Use in Glutathione Rese

  2026-07-13

  gamma-Glu-Cys (γ-Glu-Cys) provides a high-purity, well-characterized substrate for enzymatic studies in glutathione metabolism and thiol-reactive peptide synthesis. It is not intended for diagnostic or medical applications and should be used only within controlled laboratory workflows where substrate quality and stability are critical.

• Sumatriptan’s Anti-Inflammatory Actions: Systematic Review I

  2026-07-12

  This systematic review critically evaluates sumatriptan’s emerging anti-inflammatory properties, revealing its modulation of key cytokines and molecular pathways outside of migraine therapy. The findings suggest new opportunities for mechanistic research into neuroinflammation and immune modulation using triptan-class drugs.

746 records 14/50 page Previous Next First page 上5页 1112131415 下5页 Last page